Icariin prevents methylmercury-induced experimental neurotoxicity: Evidence from cerebrospinal fluid, blood plasma, brain samples, and in-silico investigations

Heliyon, Journal Year: 2024, Volume and Issue: 10(1), P. e24050 - e24050

Published: Jan. 1, 2024

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease that causes significant neurodegeneration. Methylmercury (MeHg) neurotoxin induces axonal neurodegeneration and motor nerve degeneration by destroying oligodendrocytes, degenerating white matter, inducing apoptosis, excitotoxicity, reducing myelin basic protein (MBP). This study examines the inhibition of SIRT-1 (silence information regulator 1), Nrf-2 (nuclear factor E2-related 2), HO-1 (heme oxygenase TDP-43 (TAR-DNA-binding 43) accumulation in context ALS, as well modulation these proteins icariin (15 30 mg/kg, orally), glycoside flavonoid with neuroprotective properties. Neuroprotective activates SIRT-1, Nrf-2, HO-1, mitigating inflammation neuronal injury disorders. In-vivo in-silico testing experimental ALS models confirmed efficacy modulating cellular targets. The addition sirtinol 10 an inhibitor helps determine effectiveness icariin. In this study, we also examined neurobehavioral, neurochemical, histopathological, LFB (Luxol fast blue) markers various biological samples, including Cerebrospinal fluid (CSF), blood plasma, brain homogenates (Cerebral Cortex, Hippocampus, Striatum, mid-brain, Cerebellum). These results demonstrate administration ameliorates mechanism underlying benefits likely related to regulating signaling pathways.

Language: Английский

---

Disruptions in cellular communication: Molecular interplay between glutamate/NMDA signalling and MAPK pathways in neurological disorders

Neuroscience, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Therapeutic potential of Baicalin against experimental obsessive compulsive disorder: Evidence from CSF, blood plasma, and brain analysis

Journal of Neuroimmunology, Journal Year: 2025, Volume and Issue: unknown, P. 578598 - 578598

Published: March 1, 2025

Language: Английский

---

Modulation of neural circuits by melatonin in neurodegenerative and neuropsychiatric disorders

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2024, Volume and Issue: 397(6), P. 3867 - 3895

Published: Jan. 16, 2024

Language: Английский

---

The Insulin-like Growth Factor Family as a Potential Peripheral Biomarker in Psychiatric Disorders: A Systematic Review

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(6), P. 2561 - 2561

Published: March 12, 2025

Psychiatric disorders (PDs), including schizophrenia (SZ), major depressive disorder (MDD), bipolar (BD), autism spectrum (ASD), among other disorders, represent a significant global health burden. Despite advancements in understanding their biological mechanisms, there is still no reliable objective and biomarker; therefore, diagnosis remains largely reliant on subjective clinical assessments. Peripheral biomarkers plasma or serum are interesting due to accessibility, low cost, potential reflect central nervous system processes. Among these, the insulin-like growth factor (IGF) family, IGF-1, IGF-2, IGF-binding proteins (IGFBPs), has gained attention for its roles neuroplasticity, cognition, neuroprotection, as well capability cross blood–brain barrier. This review evaluates evidence IGF family alterations PDs, with special focus SZ, MDD, BD, while also addressing PDs covering almost 40 years of history. In SZ patients, IGF-1 have been linked metabolic dysregulation, treatment response, hypothalamic–pituitary–adrenal axis dysfunction. MDD appears compensate impaired neurogenesis, although findings inconsistent. Emerging studies IGF-2 IGFBPs suggest across PDs. While promising, heterogeneity methodological limitations highlights need further research validate IGFs psychiatric biomarkers.

Language: Английский

---

Therapeutic efficacy of Genistein in activation of neuronal AC/cAMP/CREB/PKA and mitochondrial ETC-Complex pathways in experimental model of autism: Evidence from CSF, blood plasma and brain analysis

Brain Research, Journal Year: 2024, Volume and Issue: 1846, P. 149251 - 149251

Published: Oct. 9, 2024

Language: Английский

---